Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: Results of a phase II clinical study

Giammaria Fiorentini, Camillo Aliberti, Gina Turrisi, Alessandro Del Conte, Susanna Rossi, Giorgio Benea, Petros Giovanis

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Since November 2005 a clinical trial of intraarterial hepatic chemoembolization (TACE) with irinotecan-eluting beads has been ongoing in 20 patients affected by liver metastases from colorectal cancer in a palliative setting. A high response rate (80%), with reduction of lesional contrast enhancement in all responding patients was found. The procedure was well tolerated by most patients, with a median duration of hospitalization of 3 days (range 1-10 days). The most important adverse event was abdominal pain during the injection. Adequate supportive treatment with antibiotic and antiemetic prophylaxis, dexamethasone, and intravenous hydration is strictly necessary until the serum levels of transaminases are stabilized and in order to prevent infections. Major analgesics such as morphine must be used before and after the procedure. Our results suggest that TACE using irinotecan-eluting beads is feasible and active in pretreated patients with liver metastases from CRC.

Original languageEnglish
Pages (from-to)1085-1092
Number of pages8
JournalIn Vivo
Volume21
Issue number6
Publication statusPublished - Nov 2007

Fingerprint

irinotecan
Liver
Colorectal Neoplasms
Neoplasm Metastasis
Antiemetics
Transaminases
Hydration
Morphine
Dexamethasone
Analgesics
Anti-Bacterial Agents
Antibiotic Prophylaxis
Abdominal Pain
Hospitalization
Clinical Trials
Injections
Clinical Studies
Infection
Serum

Keywords

  • Colorectal cancer
  • DC beads
  • Hepatic angiography
  • Intraarterial chemotherapy
  • Irinotecan
  • Liver metastasis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fiorentini, G., Aliberti, C., Turrisi, G., Del Conte, A., Rossi, S., Benea, G., & Giovanis, P. (2007). Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: Results of a phase II clinical study. In Vivo, 21(6), 1085-1092.

Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads : Results of a phase II clinical study. / Fiorentini, Giammaria; Aliberti, Camillo; Turrisi, Gina; Del Conte, Alessandro; Rossi, Susanna; Benea, Giorgio; Giovanis, Petros.

In: In Vivo, Vol. 21, No. 6, 11.2007, p. 1085-1092.

Research output: Contribution to journalArticle

Fiorentini, G, Aliberti, C, Turrisi, G, Del Conte, A, Rossi, S, Benea, G & Giovanis, P 2007, 'Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: Results of a phase II clinical study', In Vivo, vol. 21, no. 6, pp. 1085-1092.
Fiorentini, Giammaria ; Aliberti, Camillo ; Turrisi, Gina ; Del Conte, Alessandro ; Rossi, Susanna ; Benea, Giorgio ; Giovanis, Petros. / Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads : Results of a phase II clinical study. In: In Vivo. 2007 ; Vol. 21, No. 6. pp. 1085-1092.
@article{c74a4e4445054d62891b212eb21dee47,
title = "Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: Results of a phase II clinical study",
abstract = "Since November 2005 a clinical trial of intraarterial hepatic chemoembolization (TACE) with irinotecan-eluting beads has been ongoing in 20 patients affected by liver metastases from colorectal cancer in a palliative setting. A high response rate (80{\%}), with reduction of lesional contrast enhancement in all responding patients was found. The procedure was well tolerated by most patients, with a median duration of hospitalization of 3 days (range 1-10 days). The most important adverse event was abdominal pain during the injection. Adequate supportive treatment with antibiotic and antiemetic prophylaxis, dexamethasone, and intravenous hydration is strictly necessary until the serum levels of transaminases are stabilized and in order to prevent infections. Major analgesics such as morphine must be used before and after the procedure. Our results suggest that TACE using irinotecan-eluting beads is feasible and active in pretreated patients with liver metastases from CRC.",
keywords = "Colorectal cancer, DC beads, Hepatic angiography, Intraarterial chemotherapy, Irinotecan, Liver metastasis",
author = "Giammaria Fiorentini and Camillo Aliberti and Gina Turrisi and {Del Conte}, Alessandro and Susanna Rossi and Giorgio Benea and Petros Giovanis",
year = "2007",
month = "11",
language = "English",
volume = "21",
pages = "1085--1092",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads

T2 - Results of a phase II clinical study

AU - Fiorentini, Giammaria

AU - Aliberti, Camillo

AU - Turrisi, Gina

AU - Del Conte, Alessandro

AU - Rossi, Susanna

AU - Benea, Giorgio

AU - Giovanis, Petros

PY - 2007/11

Y1 - 2007/11

N2 - Since November 2005 a clinical trial of intraarterial hepatic chemoembolization (TACE) with irinotecan-eluting beads has been ongoing in 20 patients affected by liver metastases from colorectal cancer in a palliative setting. A high response rate (80%), with reduction of lesional contrast enhancement in all responding patients was found. The procedure was well tolerated by most patients, with a median duration of hospitalization of 3 days (range 1-10 days). The most important adverse event was abdominal pain during the injection. Adequate supportive treatment with antibiotic and antiemetic prophylaxis, dexamethasone, and intravenous hydration is strictly necessary until the serum levels of transaminases are stabilized and in order to prevent infections. Major analgesics such as morphine must be used before and after the procedure. Our results suggest that TACE using irinotecan-eluting beads is feasible and active in pretreated patients with liver metastases from CRC.

AB - Since November 2005 a clinical trial of intraarterial hepatic chemoembolization (TACE) with irinotecan-eluting beads has been ongoing in 20 patients affected by liver metastases from colorectal cancer in a palliative setting. A high response rate (80%), with reduction of lesional contrast enhancement in all responding patients was found. The procedure was well tolerated by most patients, with a median duration of hospitalization of 3 days (range 1-10 days). The most important adverse event was abdominal pain during the injection. Adequate supportive treatment with antibiotic and antiemetic prophylaxis, dexamethasone, and intravenous hydration is strictly necessary until the serum levels of transaminases are stabilized and in order to prevent infections. Major analgesics such as morphine must be used before and after the procedure. Our results suggest that TACE using irinotecan-eluting beads is feasible and active in pretreated patients with liver metastases from CRC.

KW - Colorectal cancer

KW - DC beads

KW - Hepatic angiography

KW - Intraarterial chemotherapy

KW - Irinotecan

KW - Liver metastasis

UR - http://www.scopus.com/inward/record.url?scp=37349032977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349032977&partnerID=8YFLogxK

M3 - Article

C2 - 18210761

AN - SCOPUS:37349032977

VL - 21

SP - 1085

EP - 1092

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 6

ER -